Corazon (Corsee) Sanders Sells 212 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Corazon (Corsee) Sanders sold 212 shares of BeOne Medicines stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.59, for a total transaction of $65,633.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

Shares of NASDAQ:ONC traded down $2.43 during midday trading on Wednesday, reaching $300.01. 159,041 shares of the company’s stock traded hands, compared to its average volume of 252,436. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $235.57 and a one year high of $385.22. The stock has a 50 day moving average of $301.85 and a 200 day moving average of $321.12. The company has a market cap of $32.92 billion, a price-to-earnings ratio of 67.12 and a beta of 0.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion during the quarter. As a group, equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. EFG International AG purchased a new position in shares of BeOne Medicines during the fourth quarter valued at about $25,000. Leonteq Securities AG bought a new position in BeOne Medicines during the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the second quarter valued at approximately $35,000. CWM LLC grew its holdings in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC bought a new stake in BeOne Medicines in the 4th quarter worth approximately $61,000. Institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

ONC has been the topic of several recent research reports. Truist Financial reiterated a “buy” rating and issued a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Jefferies Financial Group downgraded shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their price objective for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Leerink Partners raised their target price on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Guggenheim lifted their target price on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada boosted their price target on BeOne Medicines from $423.00 to $425.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $389.15.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.